Kailera Therapeutics, Inc. Common Stock KLRA
i
Market datapartial · fetched 2026-11-12T03:21:30.179Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:37:25.867843167Z
FundamentalsAlpha Vantage · unavailable
Kailera Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 12.72 | 99.6% | 17.8% | |||
| 35Δ | 18.48 | 139.8% | 39.2% | 13.31 | 101.5% | 16.0% |
| 40Δ | 17.94 | 150.8% | 37.4% | 13.91 | 103.4% | 14.2% |
| 45Δ | 17.26 | 157.5% | 34.5% | 14.51 | 105.4% | 12.4% |
| 50Δ | 16.01 | 146.0% | 26.9% | 15.05 | 105.7% | 10.7% |
| 55Δ | 14.87 | 134.1% | 20.0% | 15.37 | 98.5% | 9.3% |
| 60Δ | 14.21 | 121.0% | 16.0% | 15.69 | 91.3% | 8.0% |
| 65Δ | 13.56 | 107.9% | 12.0% | 16.00 | 84.1% | 6.7% |
| 70Δ | 12.90 | 94.8% | 8.0% | 16.32 | 76.9% | 5.3% |
| 75Δ | 12.28 | 85.3% | 5.2% | 16.64 | 69.7% | 4.0% |
| 80Δ | 11.73 | 81.5% | 4.1% | 16.96 | 62.5% | 2.7% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.72
- IV
- 99.6%
- B/E move
- 17.8%
35Δ
- Pseudo strike
- 18.48
- IV
- 139.8%
- B/E move
- 39.2%
- Pseudo strike
- 13.31
- IV
- 101.5%
- B/E move
- 16.0%
40Δ
- Pseudo strike
- 17.94
- IV
- 150.8%
- B/E move
- 37.4%
- Pseudo strike
- 13.91
- IV
- 103.4%
- B/E move
- 14.2%
45Δ
- Pseudo strike
- 17.26
- IV
- 157.5%
- B/E move
- 34.5%
- Pseudo strike
- 14.51
- IV
- 105.4%
- B/E move
- 12.4%
50Δ
- Pseudo strike
- 16.01
- IV
- 146.0%
- B/E move
- 26.9%
- Pseudo strike
- 15.05
- IV
- 105.7%
- B/E move
- 10.7%
55Δ
- Pseudo strike
- 14.87
- IV
- 134.1%
- B/E move
- 20.0%
- Pseudo strike
- 15.37
- IV
- 98.5%
- B/E move
- 9.3%
60Δ
- Pseudo strike
- 14.21
- IV
- 121.0%
- B/E move
- 16.0%
- Pseudo strike
- 15.69
- IV
- 91.3%
- B/E move
- 8.0%
65Δ
- Pseudo strike
- 13.56
- IV
- 107.9%
- B/E move
- 12.0%
- Pseudo strike
- 16.00
- IV
- 84.1%
- B/E move
- 6.7%
70Δ
- Pseudo strike
- 12.90
- IV
- 94.8%
- B/E move
- 8.0%
- Pseudo strike
- 16.32
- IV
- 76.9%
- B/E move
- 5.3%
75Δ
- Pseudo strike
- 12.28
- IV
- 85.3%
- B/E move
- 5.2%
- Pseudo strike
- 16.64
- IV
- 69.7%
- B/E move
- 4.0%
80Δ
- Pseudo strike
- 11.73
- IV
- 81.5%
- B/E move
- 4.1%
- Pseudo strike
- 16.96
- IV
- 62.5%
- B/E move
- 2.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 101.87% | |
| 121.04% | |
| 120.32% | |
| 118.83% | |
| 121.49% | |
| 124.08% | |
| 117.08% | |
| 121.68% | |
| 119.91% | |
| 117.21% |
Biotechnology
KOD
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States…
More →KPTI
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and…
More →KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from…
More →KRRO
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent…
More →KRYS
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company…
More →KURA
Description unavailable
More →